Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clene's regulatory disclosures and financial reporting.
Clene Inc. presented new clinical data at ECTRIMS 2025 showing CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. The company furnished a poster as Exhibit 99.1 and a press release as Exhibit 99.2 in an 8-K dated September 25, 2025. The filing states the furnished materials are incorporated by reference for disclosure purposes but are not "filed" under Section 18 of the Exchange Act. No numerical efficacy, patient counts, statistical measures, or detailed clinical results are included in the text of this Current Report.
Clene Inc. reported an insider grant: Robert Dee Etherington, who is listed as both a director and the President & CEO, received a grant of option rights to purchase 10,000 shares of common stock on 09/18/2025 under the Clene Amended 2020 Stock Plan at an exercise price of $6.32 per share. The options vest immediately, are exercisable as granted, and expire on 09/17/2035. The filing shows direct beneficial ownership of the 10,000 underlying shares following the grant. The Form 4 was signed by a power of attorney on 09/19/2025.
Clene Inc. reported a compensation-related insider transaction: Chief Financial Officer Morgan R. Brown received a stock option for 10,000 shares of common stock with an exercise price of $6.32 per share. The option grant was dated 09/18/2025 and is exercisable through 09/17/2035. The filing states the options vest immediately upon grant, and following the grant the reporting person beneficially owns 10,000 underlying shares through the option. The grant was made under the company’s Amended 2020 Stock Plan.
Mark Mortenson, Chief Science Officer of Clene Inc. (CLNN / reported symbol CLNNW), was granted a stock option for 10,000 shares of common stock on 09/18/2025. The option has an exercise price of $6.32 per share, vests immediately upon grant, and expires on 09/17/2035. Following the grant, the filing reports beneficial ownership of 10,000 underlying shares attributable to the option. The Form 4 was signed by a power of attorney, Jerome T. Miraglia, on 09/19/2025. The filing indicates it was submitted by one reporting person and lists the reporting person’s Salt Lake City address.
Clene Inc. has an ongoing equity distribution agreement with Canaccord Genuity LLC dated April 28, 2025, authorizing offers and sales of up to $25,000,000 of common stock. Through this program the company previously sold common stock totaling approximately $3,706,213. On September 5, 2025 Clene filed a prospectus supplement adding $6,280,000 of additional shares available for sale under the agreement. The legal opinion from Holland & Knight LLP regarding the validity of the shares is filed as Exhibit 5.1 and is incorporated by reference.
Clene Inc. is updating its at-the-market stock offering program so it may sell up to $6,280,000 of common stock from time to time through Canaccord Genuity under an existing equity distribution agreement. The overall program allows sales of up to $25,000,000, but this supplement limits new potential sales to $6,280,000 because of Form S-3 public float restrictions and prior usage.
Clene has already sold shares of common stock with a maximum aggregate gross sales price of $3,706,213 under prior supplements and has sold $12.6 million of securities in total in the last 12 months under the same SEC size constraint. As of this supplement, the company’s public float is about $56.7 million, based on 8,812,826 non‑affiliate shares at $6.43 per share. Canaccord will act as sales agent on commercially reasonable efforts terms and earn up to 3.0% of the gross sales price per share as commission.
Clene Inc. files a preliminary shelf registration covering up to 491,496 shares of common stock for resale from time to time by existing selling securityholders. These shares may be issued upon conversion of 271,902 shares’ worth of 2024 Convertible Interest on senior secured convertible notes and 219,594 shares issuable upon conversion of additional 2025 senior secured convertible promissory notes. As of September 3, 2025, Clene had 10,030,386 shares of common stock outstanding. The company will not receive any proceeds from resale of these shares, though it has already received cash from issuing the notes.
Clene is a clinical-stage pharmaceutical company developing proprietary clean-surfaced nanocrystal (CSN®) therapeutics for neurodegenerative diseases including ALS, multiple sclerosis and Parkinson’s disease, and currently has no approved drugs and limited supplement revenue. The prospectus highlights FDA engagement on a potential accelerated approval pathway for ALS therapy CNM-Au8, ongoing and planned Phase 2/3 trials in ALS and MS, and notes recurring losses, low cash balances, covenant requirements under its 2024 notes and substantial doubt about its ability to continue as a going concern without additional financing.
Clene Inc. (CLNN) insider sale reported. General Resonance LLC reported a sale of 3,401 shares of Clene common stock on 08/21/2025 at a price of $5.34 per share, leaving beneficial ownership of 704,591 shares. The Form 4 was filed by one reporting person and signed by Heidi Ley.
Clene Inc. (CLNN) filed a Form 4 disclosing that director Vallerie McLaughlin was granted a stock option to buy 4,092 shares of common stock. The option has an exercise price of $3.60 per share, vests immediately, and covers 4,092 underlying shares. The option grant is exercisable through an expiration date of 08/13/2035. The transaction date reported is 08/14/2025. The filing indicates the Form 4 was submitted by one reporting person and was signed under power of attorney.
Clene Inc. (CLNN) reported a Section 16 Form 4 disclosing that director David J. Matlin was granted a stock option on 08/14/2025 for 7,255 shares of common stock under the companys Amended 2020 Stock Plan. The option has an exercise price of $3.60 per share, vests immediately upon grant, and is exercisable through an expiration date of 08/13/2035. Following the grant, Mr. Matlin beneficially owns 7,255 underlying shares via this option, held in a direct ownership form. The Form 4 was filed by one reporting person and signed via POA.